Hainan Huluwa Pharmaceutical Group Co Ltd

ST Hulubao (605199.SH) released its 2026 interim report, swinging from profit to loss, with net profit attributable to the parent company at negative 113 million yuan, a decrease of 116 million yuan compared with the same period last year, down 4805.36% year-on-year. Total operating revenue was 241 million yuan, down 52.55% year-on-year. Net cash inflow from operating activities was 44.4934 million yuan. The company's asset-liability ratio rose to 85.71%, gross margin fell to 16.44%, ROE was negative 37.91%, and diluted earnings per share was negative 0.28 yuan.

ST Hulubao released its 2026 interim report, showing first-half operating revenue of 241 million yuan, down 52.6 percent year on year, and a loss of 113 million yuan, swinging from profit to loss compared with the same period last year. Net loss attributable to the parent after deducting non-recurring items was 119 million yuan, widening from 18.78 million yuan in the same period last year. Net operating cash flow was 44.49 million yuan, up 214.4 percent year on year. In the second quarter, operating revenue was 94.74 million yuan, down 44.5 percent year on year, and net loss attributable to the parent was 84.43 million yuan, widening from 21.94 million yuan in the same period last year. As of the end of the second quarter, total assets were 2.419 billion yuan, down 7.1 percent from the end of the previous year, and net assets attributable to the parent were 299 million yuan, down 27.5 percent from the end of the previous year. The company said its main business has not undergone any major changes, and it continues to focus on the research, development, production and sales of pediatric medicines, holding 359 drug approval numbers, of which 130 are products currently in production and on sale, and 118 are included in the national medical insurance catalogue.

ST Hulwa disclosed its semi-annual report on August 26. In the first half of 2026, the company achieved operating revenue of 241 million yuan, down 52.55 percent year-on-year. Net profit attributable to shareholders of the listed company was negative 113 million yuan, compared with a profit of 2.4098 million yuan in the same period last year, swinging from profit to loss year-on-year. During the reporting period, affected by the overall market environment and supply-demand dynamics among other factors, the company's operating revenue declined year-on-year.

Hainan Huluwa Pharmaceutical Group Co., Ltd. has received consecutive administrative penalties from the Hainan Bureau of the China Securities Regulatory Commission and disciplinary actions from the Shanghai Stock Exchange due to false records in its 2023 annual report and 2024 semi-annual report. Investigations found that the company inflated its 2023 annual revenue by 110 million yuan, accounting for 5.77% of the disclosed revenue for that period, and inflated total profit by 89.58 million yuan, representing 66.11% of the disclosed total profit. In its 2024 semi-annual report, the company understated revenue by 42.6 million yuan and understated total profit by 27.66 million yuan. The Hainan Bureau imposed a warning and a fine of 7 million yuan on the company. Chairman and actual controller Liu Jingping was fined a total of 10.5 million yuan, then-chief financial officer Yu Hui was fined 2.5 million yuan, and then-board secretary Wang Qingtao was fined 1.5 million yuan. On the same day, the Shanghai Stock Exchange publicly reprimanded the company and the responsible individuals, and decided not to accept any listing application documents from the company for three years. Additionally, the company was criticized for violations related to related-party transactions. The company's performance declined sharply in 2025, with revenue falling 36.27% year-on-year to 901 million yuan and a net loss of 287 million yuan. For the first half of 2026, it expects a loss of between 98 million and 118 million yuan.

ST Hulubao has received an administrative penalty decision from the Hainan Regulatory Bureau of the China Securities Regulatory Commission for false records in its 2023 annual report and 2024 semi-annual report. Investigations found that the company overstated operating revenue by 110,019,632.03 yuan and inflated total profit by 89,580,304.46 yuan in its 2023 annual report, while understating operating revenue by 42,600,971.32 yuan and reducing total profit by 27,661,119.92 yuan in its 2024 semi-annual report. The company was given a warning and fined 7 million yuan. Liu Jingping, then chairperson and general manager, as the directly responsible supervisor and actual controller, was fined a total of 10.5 million yuan. Yu Hui, then director and chief financial officer, was fined 2.5 million yuan, and Wang Qingtao, then board secretary, was fined 1.5 million yuan.

On July 17, securities regulators issued administrative penalty decisions or advance notices to five A-share companies on the same day. ST Hulubao, ST Yingfei, and ST Guangtang were involved in financial fraud, while ST Xinhuajin and Black Sesame were involved in fund misappropriation. ST Hulubao was fined 7 million yuan by the Hainan Securities Regulatory Bureau for false records in its 2023 annual report and 2024 semi-annual report, with responsible individuals fined a total of 14.5 million yuan. ST Yingfei faces a proposed fine of 5.5 million yuan from the Shenzhen Securities Regulatory Bureau because its subsidiary inflated revenue and profits, with nine responsible individuals facing proposed fines totaling 12 million yuan. ST Guangtang faces a proposed fine of 4 million yuan from the Guangxi Securities Regulatory Bureau due to false records in its annual report caused by cross-period revenue recognition at its subsidiary, with five responsible individuals facing proposed fines totaling 5.3 million yuan. ST Xinhuajin faces a proposed fine of 4.55 million yuan from the Qingdao Securities Regulatory Bureau for failing to disclose in a timely manner cumulative non-operating fund misappropriation by related parties amounting to 3.936 billion yuan. Its actual controller Zhang Jianhua faces a proposed fine of 6.1 million yuan, and seven other responsible individuals face proposed fines totaling 7.15 million yuan. Black Sesame was fined 1.8 million yuan by the Guangxi Securities Regulatory Bureau because its subsidiary had 186 million yuan of funds misappropriated by related parties for non-operating purposes without disclosure. Its then actual controller Wei Qingwen was fined 5 million yuan, and three other responsible individuals were fined a total of 1.9 million yuan. Experts interviewed said that multiple companies receiving penalties on the same day shows that regulators have achieved routine inspections and batch processing of listed companies' violations, sending a regulatory signal of zero tolerance, full coverage, and full accountability.